Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 393-400

  Shimoda, Kazutaka ^a,b   Jerling, Markus ^a,c   Böttiger, Ylva ^a   Yasuda, Shin ^b   Morita, Sachiyo ^b   Bertilsson, Leif ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c PFIZER INC   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BROMAZEPAM; BROTIZOLAM; CLOMIPRAMINE; DIAZEPAM; DRUG METABOLITE; ETIZOLAM; FLUNITRAZEPAM; FLURAZEPAM; HALOXAZOLAM; NITRAZEPAM; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; NORCLOMIPRAMINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; ETHNIC GROUP; FEMALE; HUMAN; JAPAN; MALE; ORAL DRUG ADMINISTRATION; POPULATION DYNAMICS; PRIORITY JOURNAL; SWEDEN; ALGORITHM; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOMIPRAMINE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; SWEDEN;

EID: 0032589337     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00002     Document Type: Article

References (38)

1. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1994;25:1-53.
2. Bertilsson L, Dahl ML. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
3. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
4. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
5. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
6. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55:518-27.
7. Yamashita I, Asano Y. Tricyclic antidepressants. Therapeutic plasma levels. Psychopharmacol Bull 1979;15:40-1.
8. Allen JJ, Rack PH, Vaddadi KS. Differences in the effect of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgrad Med J 1977;53:79-86.
9. Rudorfer MV, Lane EA, Chang WH, Zhang M, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian. Br J Clin Pharmacol 1984;17:433-40.
10. Kishimoto A, Hollister LE. Nortriptyline kinetics in Japanese and Americans. J Clin Psychopharmacol 1984;4:171-2.
11. Pi EH, Tran-Johnson TK, Walker NR, Cooper MA, Suckow RF, Gray GE. Pharmacokinetics of desipramine in Asian and Caucasians volunteers. Psychopharmacol Bull 1989;25:483-7.
12. Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T, Takahashi S. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation and glucuronidation. Neuropsychopharmacology 1995;12:323-33.
13. Fekete J, Del Castilho P, Kraak JC. Reversed-phase liquid chromatography for the separation of chlorpromazine, imipramine and some of their metabolites. J Chromatogr 1981;204:319-27.
14. Shimoda K, Minowada T, Noguchi T, Takahashi S. Interindividual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population. J Clin Psychopharmacol 1993;13:181-8.
15. Kisor DF, Watling SM, Zarowitz BJ, Jelliffe.RW. Population pharmacokinetics of gentamicin. Use of the nonparametric estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22: 447-67.
16. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447-67.
17. Silver B, Poland RE, Lin KM. Ethnicity and the pharmacology of tricyclic antidepressants. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and psychobiology of ethnicity. Washington, DC: American Psychiatric Press, 1993:61-89.
18. Evans LEJ, Bett JHN, Cox JR, Dubois JP, van Hees T. The bioavailability of oral and parenteral clomipramine (Anafranil). Prog Neuropsychopharmacol 1980;4:293-302.
19. Nagy A, Johansson R. The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology (Berl) 1977;54:125-31.
20. Mellström B, Säwe J, Bertilsson L, Sjöqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmoker. Clin Pharmacol Ther 1986;39:369-71.
21. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
22. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoform and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-7.
23. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4[prime]-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994;37:237-42.
24. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
25. Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450 s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-64.
26. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochrome P450 therapeutically relevant in vivo. Pharmacogenetics 1994;4:359-62.
27. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
28. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressants demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993;110:302-8.
29. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
30. Härtter S, Arand M, Oesch F, Hiemke C. Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine. Psychopharmacology (Berl) 1995;117:149-53.
31. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br̈sen K. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
32. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
33. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations? Clin Pharmacol Ther 1993;43:405-11.
34. Nielsen KK, Brøsen K, Gram LF, The Danish University Antidepressant Group. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1992;43:405-11.
35. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
36. Johansson I, Oscarson M, Yue Q, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
37. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-63.
38. Träskman L, Bertilsson L, Åsberg M, Crönholm B, Mellström B, Neckers LM, Sjöqvist F, Thoren P, Tybring G. Plasma levels of chlorimipramine and its demethyl metabolites during treatment of depression. Clin Pharmacol Ther 1979;26:600-10.